Large-scale radiomic profiling of recurrent glioblastoma identifies an imaging predictor for stratifying anti-angiogenic treatment response

PURPOSE: Antiangiogenic treatment with bevacizumab, a monoclonal antibody to the vascular endothelial growth factor, is the single most widely used therapeutic agent for patients with recurrent glioblastoma (GB). A major challenge is that there are currently no validated biomarkers that can predict...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cancer Res
Glavni autori: Kickingereder, Philipp, Götz, Michael, Muschelli, John, Wick, Antje, Neuberger, Ulf, Shinohara, Russell T, Sill, Martin, Nowosielski, Martha, Schlemmer, Heinz-Peter, Radbruch, Alexander, Wick, Wolfgang, Bendszus, Martin, Maier-Hein, Klaus H, Bonekamp, David
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5503450/
https://ncbi.nlm.nih.gov/pubmed/27803067
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0702
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items